Company research
ANGIODYNAMICS INC
CIK 1275187Updated Nov 6, 2026
SecurityANGO · NASDAQ · equity
ANGO price & chart
Loading TradingView…
NASDAQ:ANGO on TradingView ↗About the company
AngioDynamics is a leading and transformative medical technology company focused on restoring healthy blood flow in the body’s vascular system, expanding cancer treatment options and improving quality of life for patients. The Company’s innov ative technologies and devices are chosen by talented physicians in fast-growing healthcare markets to treat unmet patient needs. For more information, visit www.angiodynamics.com.
In the news
No coverage from other publishers is available.
Recent filings
10-Q filing
DEFA14A filing
DEF 14A filing
Results of Operations and Financial Condition · Regulation FD Disclosure
Items 2.02, 7.01, 9.01
Entry into a Material Definitive Agreement · Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements
Items 1.01, 5.02, 9.01
Show 5 more recent filings
Financials
FY 2026 · USDSource
Source
Source
Source
Source
Source
balance sheet · annual statements
| Line item | Q3 2026 | Q3 2025 | Q3 2024 | Q2 2026 | Q2 2025 | Q1 2027 | Q1 2026 | Q1 2025 | FY 2026 | FY 2025 | FY 2024 | FY 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ASSETS | ||||||||||||
| AssetsUSD | 260,678,000Source | 285,415,000Source | 324,842,000Source | 269,681,000Source | 291,550,000Source | 241,933,000Source | 265,642,000Source | 293,628,000Source | 267,163,000Source | 280,144,000Source | 317,671,000Source | 532,637,000Source |
| Property, Plant and Equipment, NetUSD | 29,142,000Source | 32,530,000Source | 37,040,000Source | 30,527,000Source | 32,977,000Source | 27,728,000Source | 31,066,000Source | 34,377,000Source | 27,097,000Source | 32,300,000Source | 35,666,000Source | 44,384,000Source |
| GoodwillUSD | — | — | 0Source | — | — | — | — | — | — | — | 0Source | 159,238,000Source |
| Intangible Assets, Net (Excluding Goodwill)USD | 65,486,000Source | 70,931,000Source | 81,570,000Source | 66,732,000Source | 73,110,000Source | 61,894,000Source | 68,380,000Source | 75,774,000Source | 67,209,000Source | 69,116,000Source | 77,383,000Source | 111,144,000Source |
| Current assets: | ||||||||||||
| Cash and Cash Equivalents, at Carrying ValueUSD | 37,810,000Source | 44,760,000Source | 78,451,000Source | 41,638,000Source | 54,089,000Source | 33,973,000Source | 38,762,000Source | 55,005,000Source | 53,864,000Source | 55,893,000Source | 76,056,000Source | 44,620,000Source |
| Accounts Receivable, after Allowance for Credit Loss, CurrentUSD | 45,552,000Source | 43,468,000Source | 49,475,000Source | 44,434,000Source | 43,158,000Source | 44,905,000Source | 42,643,000Source | 39,563,000Source | 48,325,000Source | 42,890,000Source | 43,610,000Source | 52,826,000Source |
| Inventory, NetUSD | 58,578,000Source | 63,105,000Source | 58,068,000Source | 65,569,000Source | 65,918,000Source | 54,953,000Source | 62,255,000Source | 64,700,000Source | 52,436,000Source | 62,006,000Source | 60,616,000Source | 55,325,000Source |
| Assets, CurrentUSD | 155,552,000Source | 172,273,000Source | 196,907,000Source | 161,349,000Source | 175,360,000Source | 143,003,000Source | 156,656,000Source | 172,594,000Source | 163,394,000Source | 168,324,000Source | 193,253,000Source | 163,542,000Source |
| Prepaid Expense and Other Assets, CurrentUSD | 13,612,000Source | 15,440,000Source | 10,913,000Source | 9,708,000Source | 12,195,000Source | 9,172,000Source | 12,996,000Source | 13,326,000Source | 8,769,000Source | 7,535,000Source | 12,971,000Source | 4,617,000Source |
| Operating Lease, Right-of-Use AssetUSD | 5,408,000Source | 4,297,000Source | 3,854,000Source | 5,724,000Source | 4,803,000Source | 4,920,000Source | 3,411,000Source | 5,313,000Source | 5,053,000Source | 3,850,000Source | 5,804,000Source | 5,113,000Source |
| Other Assets, NoncurrentUSD | 10,498,000Source | 9,681,000Source | 9,325,000Source | 11,073,000Source | 10,103,000Source | 9,308,000Source | 9,540,000Source | 10,883,000Source | 9,463,000Source | 10,404,000Source | 11,369,000Source | 10,676,000Source |
| LIABILITIES AND EQUITY | ||||||||||||
| LiabilitiesUSD | 87,321,000Source | 99,545,000Source | 106,144,000Source | 93,348,000Source | 104,782,000Source | 77,970,000Source | 86,787,000Source | 97,046,000Source | 96,338,000Source | 97,174,000Source | 112,085,000Source | 154,341,000Source |
| Stockholders’ equity: | ||||||||||||
| Preferred Stock, Value, IssuedUSD | 0Source | 0Source | 0Source | 0Source | 0Source | 0Source | 0Source | 0Source | 0Source | 0Source | 0Source | 0Source |
| Common Stock, Value, IssuedUSD | 387,000Source | 385,000Source | 385,000Source | 386,000Source | 384,000Source | 388,000Source | 386,000Source | 386,000Source | 387,000Source | 385,000Source | 385,000Source | 382,000Source |
| Retained Earnings (Accumulated Deficit)USD | -454,534,000Source | -423,147,000Source | -381,755,000Source | -446,450,000Source | -418,740,000Source | -473,036,000Source | -440,100,000Source | -408,002,000Source | -465,939,000Source | -429,197,000Source | -395,204,000Source | -210,855,000Source |
| Accumulated Other Comprehensive Income (Loss), Net of TaxUSD | 2,706,000Source | -3,532,000Source | -2,806,000Source | 998,000Source | -3,748,000Source | 4,684,000Source | 61,000Source | -3,267,000Source | 7,675,000Source | -2,023,000Source | -4,365,000Source | -4,723,000Source |
| Stockholders' Equity Attributable to ParentUSD | 173,357,000Source | 185,870,000Source | 218,698,000Source | 176,333,000Source | 186,768,000Source | 163,963,000Source | 178,855,000Source | 196,582,000Source | 170,825,000Source | 182,970,000Source | 205,586,000Source | 378,296,000Source |
| Additional Paid in Capital, Common StockUSD | 632,179,000Source | 619,545,000Source | 608,588,000Source | 628,780,000Source | 616,253,000Source | 639,308,000Source | 625,889,000Source | 613,730,000Source | 636,083,000Source | 621,186,000Source | 610,484,000Source | 599,206,000Source |
| Liabilities and EquityUSD | 260,678,000Source | 285,415,000Source | 324,842,000Source | 269,681,000Source | 291,550,000Source | 241,933,000Source | 265,642,000Source | 293,628,000Source | 267,163,000Source | 280,144,000Source | 317,671,000Source | 532,637,000Source |
| Current liabilities: | ||||||||||||
| Liabilities, CurrentUSD | 66,066,000Source | 77,971,000Source | 85,874,000Source | 71,963,000Source | 88,595,000Source | 59,689,000Source | 68,282,000Source | 76,699,000Source | 74,717,000Source | 76,197,000Source | 91,155,000Source | 83,825,000Source |
| Operating Lease, Liability, CurrentUSD | 1,313,000Source | 1,826,000Source | 1,645,000Source | 1,312,000Source | 1,878,000Source | 1,404,000Source | 1,773,000Source | 1,931,000Source | 1,296,000Source | 1,840,000Source | 1,975,000Source | 1,922,000Source |
| Accounts Payable, CurrentUSD | 29,105,000Source | 30,265,000Source | 35,152,000Source | 35,390,000Source | 34,746,000Source | 26,579,000Source | 31,882,000Source | 31,272,000Source | 31,513,000Source | 33,291,000Source | 37,751,000Source | 40,445,000Source |
| Operating Lease, Liability, NoncurrentUSD | 4,181,000Source | 2,571,000Source | 2,322,000Source | 4,478,000Source | 3,030,000Source | 3,635,000Source | 1,725,000Source | 3,490,000Source | 3,860,000Source | 2,106,000Source | 3,939,000Source | 3,316,000Source |
| Other Liabilities, NoncurrentUSD | 16,701,000Source | 17,371,000Source | 14,353,000Source | 17,054,000Source | 11,853,000Source | 13,601,000Source | 14,237,000Source | 15,721,000Source | 16,305,000Source | 16,904,000Source | 16,078,000Source | 3,350,000Source |
| Additional Financial Items | ||||||||||||
| Accrued Liabilities, CurrentUSD | 32,303,000Source | 36,949,000Source | 30,963,000Source | 29,853,000Source | 39,919,000Source | 28,811,000Source | 27,657,000Source | 34,108,000Source | 38,909,000Source | 35,518,000Source | 41,098,000Source | 26,617,000Source |
| Deferred Tax Liabilities, NetUSD | — | — | — | — | — | — | — | — | 5,230,000Source | 4,058,000Source | 4,812,000Source | 12,765,000Source |
| Long-term DebtUSD | — | — | — | — | — | — | — | — | — | — | 0Source | 49,818,000Source |
cash flow · annual statements
| Line item | Q4 2026 | Q4 2025 | Q3 2026 | Q3 2025 | Q2 2026 | Q2 2025 | Q1 2027 | Q1 2026 | FY 2026 | FY 2025 | FY 2024 | FY 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash flows from operating activities: | ||||||||||||
| Adjustments to reconcile net income to net cash provided by operating activities: | ||||||||||||
| Depreciation and amortization | — | — | — | — | — | — | —Source | —Source | —Source | —Source | —Source | —Source |
| Share-based Payment Arrangement, Noncash ExpenseUSD | — | — | — | — | — | — | 4,502,000Source | 4,470,000Source | 13,960,000Source | 9,772,000Source | 10,529,000Source | 11,158,000Source |
| Changes in operating assets and liabilities: | ||||||||||||
| Increase (Decrease) in Accounts ReceivableUSD | — | — | — | — | — | — | -3,471,000Source | -139,000Source | 5,750,000Source | -23,000Source | -7,894,000Source | 1,299,000Source |
| Increase (Decrease) in InventoriesUSD | — | — | — | — | — | — | 2,715,000Source | 192,000Source | -10,047,000Source | 1,347,000Source | 9,410,000Source | 8,198,000Source |
| Deferred Income Tax Expense (Benefit)USD | — | — | — | — | — | — | -306,000Source | -16,000Source | 143,000Source | -988,000Source | -7,968,000Source | -2,311,000Source |
| Net Cash Provided by (Used in) Operating ActivitiesUSD | — | — | — | — | — | — | -15,330,000Source | -15,914,000Source | 3,089,000Source | -10,128,000Source | -28,158,000Source | 78,000Source |
| Cash flows from investing activities: | ||||||||||||
| Net Cash Provided by (Used in) Investing ActivitiesUSD | — | — | — | — | — | — | -3,148,000Source | -1,551,000Source | -5,949,000Source | -10,178,000Source | 123,717,000Source | -9,746,000Source |
| Payments to Acquire Property, Plant, and EquipmentUSD | — | — | — | — | — | — | 379,000Source | 731,000Source | 2,581,000Source | 4,464,000Source | 2,518,000Source | 3,812,000Source |
| Cash flows from financing activities: | ||||||||||||
| Payments for Repurchase of Common StockUSD | — | — | — | — | — | — | — | 0Source | 0Source | 1,670,000Source | — | — |
| Net Cash Provided by (Used in) Financing ActivitiesUSD | — | — | — | — | — | — | -1,375,000Source | 143,000Source | 564,000Source | -255,000Source | -64,248,000Source | 25,420,000Source |
| Repayments of Long-term DebtUSD | — | — | — | — | — | — | — | — | 0Source | 0Source | 50,000,000Source | 45,000,000Source |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate EffectUSD | — | — | — | — | — | — | -19,891,000Source | -17,131,000Source | -2,029,000Source | -20,163,000Source | 31,436,000Source | 15,795,000Source |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash EquivalentsUSD | — | — | 37,810,000Source | 44,760,000Source | 41,638,000Source | 54,089,000Source | 33,973,000Source | 38,762,000Source | 53,864,000Source | 55,893,000Source | 76,056,000Source | 44,620,000Source |
| Supplemental disclosure of cash flow information: | ||||||||||||
| Income Taxes Paid, NetUSD | — | — | — | — | — | — | — | — | 405,000Source | 800,000Source | 455,000Source | 342,000Source |
| Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash and Restricted Cash EquivalentsUSD | — | — | — | — | — | — | -38,000Source | 191,000Source | 267,000Source | 398,000Source | 125,000Source | 43,000Source |
| Additional Financial Items | ||||||||||||
| Share-based Payment Arrangement, ExpenseUSD | — | — | 2,700,000Source | 2,400,000Source | 2,900,000Source | 2,500,000Source | 4,500,000Source | 4,500,000Source | 13,960,000Source | 9,772,000Source | 10,529,000Source | 11,158,000Source |
| Amortization of Intangible AssetsUSD | — | — | 2,668,000Source | 2,598,000Source | 2,643,000Source | 2,562,000Source | 2,729,000Source | 2,653,000Source | 10,682,000Source | 10,318,000Source | 13,048,000Source | 18,790,000Source |
| DepreciationUSD | — | — | — | — | — | — | — | — | 10,500,000Source | 13,500,000Source | 14,700,000Source | 11,900,000Source |
| Gain (Loss) on Disposition of AssetsUSD | — | — | — | 0Source | — | 0Source | — | — | 0Source | 0Source | 54,499,000Source | — |
| Gain (Loss) on Disposition of BusinessUSD | — | — | — | — | — | — | — | — | 0Source | 0Source | 54,499,000Source | — |
| Gain (Loss) on Disposition of Property Plant EquipmentUSD | — | — | 0Source | 0Source | 0Source | — | 0Source | 0Source | 0Source | 0Source | — | — |
| General and Administrative ExpenseUSD | — | — | 10,719,000Source | 10,490,000Source | 10,151,000Source | 10,391,000Source | 12,467,000Source | 12,555,000Source | 43,691,000Source | 42,092,000Source | 41,164,000Source | 40,003,000Source |
| GoodwillUSD | — | — | — | — | — | — | — | — | — | — | 0Source | 159,238,000Source |
| Goodwill, Impairment LossUSD | — | — | — | 0Source | — | — | — | — | 0Source | 0Source | 159,476,000Source | 14,549,000Source |
| Impairment of Intangible Assets, Finite-livedUSD | — | — | — | — | — | — | — | — | 0Source | 0Source | — | — |
| Income Tax Expense (Benefit)USD | — | — | 12,000Source | -2,000Source | -5,000Source | -110,000Source | -199,000Source | 65,000Source | 442,000Source | -39,000Source | -7,289,000Source | -1,995,000Source |
| Net Income (Loss) Attributable to ParentUSD | — | — | -8,084,000Source | -4,407,000Source | -6,350,000Source | -10,738,000Source | -7,097,000Source | -10,903,000Source | -36,742,000Source | -33,993,000Source | -184,349,000Source | -52,442,000Source |
| Operating ExpensesUSD | — | — | 54,430,000Source | 48,831,000Source | 50,908,000Source | 51,000,000Source | 55,342,000Source | 52,513,000Source | 214,819,000Source | 197,659,000Source | 401,632,000Source | 225,427,000Source |
| Operating Lease, ExpenseUSD | — | — | 542,000Source | 657,000Source | 619,000Source | 656,000Source | 558,000Source | 638,000Source | 2,345,000Source | 2,632,000Source | 2,549,000Source | 2,694,000Source |
| Other Nonoperating Income (Expense)USD | — | — | 4,967,000Source | 5,430,000Source | -128,000Source | 12,000Source | 94,000Source | -178,000Source | 3,926,000Source | 4,944,000Source | -817,000Source | -554,000Source |
| Proceeds from Stock Options ExercisedUSD | — | — | — | — | — | — | — | — | 0Source | 200,000Source | — | 300,000Source |
| Nonoperating Income (Expense) | — | — | —Source | —Source | —Source | —Source | —Source | —Source | — | — | — | — |
| Restructuring Costs | — | — | — | — | — | — | —Source | — | — | — | — | — |
income statement · annual statements
| Line item | Q4 2026 | Q4 2025 | Q3 2026 | Q3 2025 | Q2 2026 | Q2 2025 | Q1 2027 | Q1 2026 | FY 2026 | FY 2025 | FY 2024 | FY 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total RevenueUSD | — | — | 78,423,000Source | 72,004,000Source | 79,433,000Source | 72,845,000Source | 80,915,000Source | 75,711,000Source | 320,174,000Source | 292,498,000Source | 303,914,000Source | 338,752,000Source |
| Cost of RevenueUSD | — | — | 36,944,000Source | 33,147,000Source | 34,650,000Source | 32,939,000Source | 32,875,000Source | 33,854,000Source | 145,282,000Source | 134,793,000Source | 149,216,000Source | 164,506,000Source |
| Operating Income (Loss)USD | — | — | -12,951,000Source | -9,974,000Source | -6,125,000Source | -11,094,000Source | -7,302,000Source | -10,656,000Source | -39,927,000Source | -39,954,000Source | -192,435,000Source | -51,181,000Source |
| Other Nonoperating Income (Expense)USD | — | — | 4,967,000Source | 5,430,000Source | -128,000Source | 12,000Source | 94,000Source | -178,000Source | 3,926,000Source | 4,944,000Source | -817,000Source | -554,000Source |
| Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling InterestUSD | — | — | -8,072,000Source | -4,409,000Source | -6,355,000Source | -10,848,000Source | -7,296,000Source | -10,838,000Source | -36,300,000Source | -34,032,000Source | -191,638,000Source | -54,437,000Source |
| Income Tax Expense (Benefit)USD | — | — | 12,000Source | -2,000Source | -5,000Source | -110,000Source | -199,000Source | 65,000Source | 442,000Source | -39,000Source | -7,289,000Source | -1,995,000Source |
| Net Income (Loss) Attributable to ParentUSD | — | — | -8,084,000Source | -4,407,000Source | -6,350,000Source | -10,738,000Source | -7,097,000Source | -10,903,000Source | -36,742,000Source | -33,993,000Source | -184,349,000Source | -52,442,000Source |
| Earnings Per Share, BasicUSD per share | — | — | -0.19Source | -0.11Source | -0.15Source | -0.26Source | -0.17Source | -0.26Source | -0.88Source | -0.83Source | -4.59Source | -1.33Source |
| Earnings Per Share, DilutedUSD per share | — | — | -0.19Source | -0.11Source | -0.15Source | -0.26Source | -0.17Source | -0.26Source | -0.88Source | -0.83Source | -4.59Source | -1.33Source |
| Weighted Average Number of Shares Outstanding, Basicshares | — | — | 41,596,000Source | 40,853,000Source | 41,542,000Source | 40,922,000Source | 42,022,000Source | 41,174,000Source | 41,525,697Source | 40,852,564Source | 40,180,925Source | 39,480,367Source |
| Weighted Average Number of Shares Outstanding, Dilutedshares | — | — | 41,596,000Source | 40,853,000Source | 41,542,000Source | 40,922,000Source | 42,022,000Source | 41,174,000Source | 41,525,697Source | 40,852,564Source | 40,180,925Source | 39,480,367Source |
| Additional Financial Items | ||||||||||||
| Amortization of Intangible AssetsUSD | — | — | 2,668,000Source | 2,598,000Source | 2,643,000Source | 2,562,000Source | 2,729,000Source | 2,653,000Source | 10,682,000Source | 10,318,000Source | 13,048,000Source | 18,790,000Source |
| Current Income Tax Expense (Benefit)USD | — | — | — | — | — | — | — | — | 299,000Source | 949,000Source | 679,000Source | 316,000Source |
| Depreciation, Depletion and Amortization, NonproductionUSD | — | — | — | — | — | — | 5,498,000Source | 5,950,000Source | 22,955,000Source | 25,800,000Source | 27,712,000Source | 30,873,000Source |
| General and Administrative ExpenseUSD | — | — | 10,719,000Source | 10,490,000Source | 10,151,000Source | 10,391,000Source | 12,467,000Source | 12,555,000Source | 43,691,000Source | 42,092,000Source | 41,164,000Source | 40,003,000Source |
| Goodwill, Impairment LossUSD | — | — | — | 0Source | — | — | — | — | 0Source | 0Source | 159,476,000Source | 14,549,000Source |
| Gross ProfitUSD | — | — | 41,479,000Source | 38,857,000Source | 44,783,000Source | 39,906,000Source | 48,040,000Source | 41,857,000Source | 174,892,000Source | 157,705,000Source | 154,698,000Source | 174,246,000Source |
| Income (Loss) from Continuing Operations before Income Taxes, DomesticUSD | — | — | — | — | — | — | — | — | -37,787,000Source | -30,172,000Source | -177,314,000Source | -45,240,000Source |
| Interest ExpenseUSD | — | — | — | — | — | — | — | — | — | — | -1,614,000Source | 2,702,000Source |
| Interest Income (Expense), Nonoperating, NetUSD | — | — | -88,000Source | 135,000Source | -102,000Source | 234,000Source | -88,000Source | -4,000Source | -299,000Source | 978,000Source | — | — |
| Operating ExpensesUSD | — | — | 54,430,000Source | 48,831,000Source | 50,908,000Source | 51,000,000Source | 55,342,000Source | 52,513,000Source | 214,819,000Source | 197,659,000Source | 401,632,000Source | 225,427,000Source |
| Operating Lease, ExpenseUSD | — | — | 542,000Source | 657,000Source | 619,000Source | 656,000Source | 558,000Source | 638,000Source | 2,345,000Source | 2,632,000Source | 2,549,000Source | 2,694,000Source |
| Research and Development ExpenseUSD | — | — | 7,084,000Source | 6,913,000Source | 7,768,000Source | 6,434,000Source | 7,979,000Source | 6,417,000Source | 29,447,000Source | 26,222,000Source | 31,512,000Source | 29,883,000Source |
| Selling and Marketing ExpenseUSD | — | — | 27,437,000Source | 25,504,000Source | 26,711,000Source | 25,589,000Source | 29,986,000Source | 28,130,000Source | 113,401,000Source | 103,135,000Source | 102,818,000Source | 104,249,000Source |
| Nonoperating Income (Expense) | — | — | —Source | —Source | —Source | —Source | —Source | —Source | — | — | — | — |
| Restructuring Costs | — | — | — | — | — | — | —Source | — | — | — | — | — |
Filing attachments
ef20083493_ex99-1.htm · 8-K · 2026-10-08
Exhibit 99.1 AngioDynamics Reports Fiscal Year 2027 First Quarter Financial Results; Continued Execution Drives Med Tech Growth and Profitability Delivered its eighth consecutive quarter of double-digit Med Tech segment growth and positive adjusted EBITDA LATHAM, N.Y.--(BUSINESS WIRE) - Oct. 8, 2026-- AngioDynamics, Inc. (NASDAQ: ANGO), a leading and transformative medical technology company focused on restoring healthy blood flow in the body’s vascular system, expanding cancer treatment opti…
Read attachment ↗ef20083493_ex99-2.htm · 8-K · 2026-10-08
Exhibit 99.2 First Quarter FY 2027Earnings Results October 8, 2026 Forward looking statements 2 Notice Regarding Forward-Looking Statements This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements regarding AngioDynamics’ expected future financial position, results of operations, cash flows, business strategy, budgets, projected costs, capital expenditures, products, competitive positions, growth opportunit…
Read attachment ↗ef20083270_ex99-1.htm · 8-K · 2026-10-08
Exhibit 99.1 NEWS RELEASE Media Contact: Saleem Cheeks Investor Contact: Vice President, Communications 518-795-1174 Stephen Trowbridge scheeks@angiodynamics.com Media Contact: Saleem Cheeks Executive Vice President & CFO …
Read attachment ↗ef20077916_ex99-1.htm · 8-K · 2026-07-14
EX-99.1 2 ef20077916_ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 AngioDynamics Reports Record Fiscal Year 2026 Fourth Quarter and Full Year Financial Results; Continued Execution Drives Med Tech Growth and Full-Year Profitability Delivered its seventh consecutive quarter of double-digit Med Tech segment growth and positive adjusted EBITDA LATHAM, N.Y.--(BUSINESS WIRE) - July 14, 2026-- AngioDynamics, Inc. (NASDAQ: ANGO), a leading and transformative medical technology company focused on restorin…
Read attachment ↗ef20077916_ex99-2.htm · 8-K · 2026-07-14
EX-99.2 3 ef20077916_ex99-2.htm EXHIBIT 99.2 Exhibit 99.2 Fourth Quarter and Full Year 2026Earnings Results July 14, 2026 Forward looking statements 2 Notice Regarding Forward-Looking Statements This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements regarding AngioDynamics’ expected future financial position, results of operations, cash flows, business strategy, budgets, projected costs, capital expen…
Read attachment ↗ef20069681_ex99-1.htm · 8-K · 2026-04-02
EX-99.1 2 ef20069681_ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 AngioDynamics Reports Fiscal Year 2026 Third Quarter Financial Results; Sustained Double-Digit Med Tech Growth Drives Continued Profitability Med Tech segment delivered its sixth consecutive quarter of double-digit growth ─────────────────────────────────────────────────────────────────────────────────── Strong adjusted EBITDA Third consecutive quarter the Company raised full year FY 2026 guidance for net sales and Adjusted…
Read attachment ↗